The role of hemostatic system inhibitors in malignancy

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 7, 2007, Pages 621-642

  Wojtukiewicz, Marek Z ^a,b   Sierko, Ewa ^a,b   Kisiel, Walter ^c  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Regional Comprehensive Cancer Center in Bialystok   (Poland)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

AT III; Cancer; Fibrinolysis inhibitors; Hemostatic system inhibitors; Heparin; Protein C system; Protein Z; TFPI; TFPI 2; ZPI

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANGIOGENESIS INHIBITOR; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; DROTRECOGIN; FATTY ACID BINDING PROTEIN; HEPARIN; HEPARIN COFACTOR II; PLACENTA PROTEIN 5; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEASE NEXIN I; PROTEIN C; PROTEINASE INHIBITOR; RWJ 58259; SCH 79797; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ACTIVATED PROTEIN C RESISTANCE; ANGIOGENESIS; APOPTOSIS; BLEEDING; CANCER; CELL PROLIFERATION; HEMOSTASIS; HUMAN; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; NEOPLASMS;

EID: 36348999275     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-991530     Document Type: Review

References (327)

1. Callander N, Rapaport SI. Trousseau's syndrome. West J Med 1993;158:364-371
2. Naschitz JE, Yeshurun D, Lev LM. Thromboembolism in cancer. Cancer 1993;71:1384-1390
3. Hillen HFP. Thrombosis in cancer patients. Ann Oncol 2000;11(Suppl 3):273-276
4. Bick RL. Coagulation abnormalities in malignancy: a review. Semin Thromb Hemost 1992;18:353-372
5. Barnes J, Patel V, Lee M. Adenocarcinoma of the colon presenting with a Sister Mary Joseph's nodule and Trousseau's syndrome. Cutis 1995;56:270-272
6. Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992;18:104-116
7. Zacharski LR, Costantini V, Wojtukiewicz MZ, Memoli VA, Kudryk BJ. Anticoagulants as cancer therapy. Semin Oncol 1990;17:217-227
8. Lindahl AK, Sandset PM, Abildgaard U, Adersson TR, Harbitz TB. High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chir Scand 1989;155:389-393
9. Lindahl AK, Odegaard OR, Sandset PM, Harbitz TB. Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. Cancer 1992;70:2067-2072
10. Falanga A, Ofosu FA, Dalaini F, et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coagul Fibrinolysis 1994;5(Suppl 1):S19-S23
11. Gerlach R, Scheuer T, Bohm M, et al. Increased levels of plasma tissue factor pathway inhibitor in patients with glioblastoma and intracerebral metastases. Neurol Res 2003;25:335-338
12. Radziwon P, Schenk JF, Mazgajska K, et al. Tissue factor (TF) and inhibitor (TFPI) concentrations in patients with urinary tract tumors and haematological malignancies. [in Polish]. Pol Merkur Lekarski. 2002;13:308-311
13. Beecken WD, Bentas W, Engels K, et al. Reduced plasma levels of coagulation factors in relation to prostate cancer. Prostate 2002;53:160-167
14. Iversen LH, Okholm M, Thorlacius-Ussing OO. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease - a preliminary study. Thromb Haemost 1996;76:523-528
15. Erman M, Abali H, Oran B, et al. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 2004;15:1622-1626
16. Bushman JE, Palmeri D, Whinna HC, Church FC, Insight into the mechanism of asparaginase-induced depletion of antithrombin III in treatment of childhood acute lymphoblastic leukemia. Leuk Res 2000;24:559-565
17. Noda K, Wada H, Yamada N, et al. Changes of hemostatic molecular markers after gynecological surgery. Clin Appl Thromb Hemost 2000;6:197-201
18. Lee JH, Lee KH, Kim S, et al. Relevance of protein C and S, antithrombin III, von Willebrand factor, and factor VII for the development of hepatic veno-occlusive disease in patients undergoing allogenic bone marrow transplantation: a prospective study. Bone Marrow Transplant 1998;22:883-888
19. Park YD, Yasui M, Yoshimoto T, et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 1997;19:915-920
20. Nürnberger W, Michelmann I, Burdach S, Göbel U. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998;76:61-65
21. Matsumoto T, Wada H, Nishiyama H, et al. Hemostatic abnormalities and changes following bone marrow transplantation. Clin Appl Thromb Hemost 2004;10:341-350
22. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-93
23. Lindahl AK, Abildgaard U, Stokke G. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb Res 1990;59:651-656
24. Iversen N, Lindahl AK, Abildgaard U. Elevated plasma levels of the factor Xa-TFPI complex in cancer patients. Thromb Res 2002;105:33-36
25. Amirkhoshravi A, Meyer T, Chang J-Y, Amaya M, Siddiqui H, Francis JL. Tissue factor pathway inhibitor reduces experimental lung metastases of B16 melanoma. Thromb Haemost 2002;87:930-936
26. Hembrough TA, Swartz GM, Papathanassiu A, et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63:2997-3000
27. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205-8209
28. Müller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor dependent experimental metastasis. J Clin Invest 1998;101:1372-1378
29. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis 1994-95;14:109-122
30. Honn KV, Tang GT, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. Semin Thromb Hemost 1992;18:392-415
31. Donnelly KM, Bromberg ME, Milstone A, et al. Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro. Thromb Haemost 1998;79:1041-1047
32. Chachinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989;7:993-1002
33. Hejna M, Raderer M, Zielinsky CC. Inhibition of metastasis by anticoagulants. J Natl Cancer Inst 1999;91:22-36
34. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small-cell lung cancer. Cancer 1994;74:38-45
35. Wojtukiewicz MZ, Kozlowski L, Ostrowska K, Dmitruk A, Zacharski LR. Low molecular heparin treatment for malignant melanoma: a pilot clinical trial. Thromb Haemost 2003;89:405-407
36. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 1984;53:2046-2052
37. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-1948
38. Mousa SA, Linhardt R, Francis J, Amirkhosravi A. Antimetastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 2006;96:816-821
39. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 2004;30:5-20
40. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001;3:371-384
41. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1995;1:27-31
42. Shoji M, Abe K, Nawroth PP, et al. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med 1997;7:52-59
43. Ott I, Fischer EG, Miyagi Y, et al. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998;140:1241-1253
44. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10:502-509
45. Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 2005;105:2384-2391
46. Amirkhosravi A, Meyer T, Desai H, et al. TFPI carboxyterminal peptide exhibits anticoagulant activity and suppresses proliferation of melanoma and endothelial cells. Blood 2001;98:66b
47. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SA. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993;69:366-369
48. Sierko E, Zawadzki RJ, Zimnoch L, Sulkowski S, Wojtukiewicz MZ. Expression of blood coagulation inhibitors in colon cancer. [in Polish] Pol Merkur Lekarski 2006;20:462-467
49. Wojtukiewicz MZ, Rucinska M, Zacharski LR, et al. Localization of blood coagulation factors in situ in pancreatic carcinoma. Thromb Haemost 2001;86:1416-1420
50. Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel B. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost 2003;29:291-299
51. Wojtukiewicz MZ, Zacharski LR, Rucinska M, et al. Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost 1999;82:1659-1662
52. Sierko E, Sawicki Z, Butkiewicz A, Zimnoch L, Kisiel W, Wojtukiewicz M. TFPI (tissue factor pathway inhibitor) is present in breast cancer tumor. [abstract]Blood 2006;108:4035
53. Kurer MA. Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep 2006; (abst)
54. Sevinsky JR, Rao LVM, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996;133:293-304
55. Ruf W, Müller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996;3:379-384
56. Ruf W, Müller BM. Tissue factor signaling. Thromb Haemost 1999;82:175-182
57. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer 1990;65:481-485
58. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989;62:1062-1066
59. Fischer EG, Riewald M, Huang HY, et al. Tumor cell adhesion and migration supported by interaction of a receptor-protease complex with its inhibitor. J Clin Invest 1999;104:1213-1221
60. Ruf W, Seftor EA, Petrovan RJ, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003;63:5381-5389
61. Sprecher CA, Kisiel W, Mathews S, Foster DC. Molecular cloning, expression, and partial characterization of a second tissue-factor-pathway- inhibitor. Proc Natl Acad Sci USA 1994;91:3353-3357
62. Peterson LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996;35:266-272
63. Kisiel W, Sprecher CA, Foster DC. Evidence that a second tissue factor pathway inhibitor (TFPI-2) and placental protein 5 are equivalent. Blood 1994;84:4384-4385
64. Chand HS, Schmidt AE, Bajaj SP, Kisiel W. Structure-function analysis of the reactive site in the first Kunitz-type domain of human factor pathway inhibitor-2. J Biol Chem 2004;279:17500-17507
65. Bohn H, Winckler W. Isolierung und Charakterisierung des Plazenta-Proteins PP5. Arch Gynaek 1977;223:179-186
66. Siiteri JE, Koistinen HAT, Salem HAT, Bohn H, Seppaelae M. Placental protein 5 is related to blood coagulation and fibrinolytic systems. Life Sci 1982;30:1885-1891
67. Meisser A, Bischof P, Bohn H. Placental protein 5 (PP5) inhibits thrombin-induced coagulation of fibrinogen. Arch Gynecol 1985;236:197-201
68. Miyagi Y, Koshikawa N, Yasumitsu H, et al. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: identification as placental protein 5 and tissue factor pathway inhibitor-2. J Biochem (Tokyo) 1994;116:939-942
69. Iino M, Foster DC, Kisiel W. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 1998;18:40-46
70. Wahlstroem T, Bohn H, Seppaelae M. Immunohistochemical demonstration of placental protein 5 (PP5) - like material in the seminal vesicles and the ampullar part of vas deferens. Life Sci 1982;31:2723-2725
71. Wojtukiewicz MZ, Sierko E, Zimnoch L, Koztowski L, Sulkowski S, Kisiel W. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003;90:140-146
72. Rollin J, Régina S, Vourc'h P, et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer 2007;56:273-280
73. Rollin J, Iochmann S, Bléchet C, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005;92:775-783
74. Wong CM, Ng YL, Lee JM, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007;45:1129-1138
75. Rao CN, Lakka SS, Kin Y, et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 2001;7;570-576
76. Sato N, Parker AR, Fukushima N, et al. Epigenetic inactivation of TFPI-2 as a mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005;24:850-858
77. Udagawa K, Miyagi Y, Hirahara F, et al. Specific expression of PP5/TFPI-2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 1998;19:217-223
78. Izumi H, Takahashi C, Oh J, Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogene. FEBS Lett 2000;481:3136
79. Saito E, Okamoto A, Saito M, et al. Genes associated with the genesis of leiomyoma of the uterus in a commonly deleted chromosomal region at 7q22. Oncol Rep 2005;13:469-472
80. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001;20:173-193
81. Sell SM, Tullis C, Stracner D, Song CY, Gewin J. Minimal interval defined on 7q in uterine leiomyoma. Cancer Genet Cytogenet 2005;157:67-69
82. Nobeyama Y, Okochi-Takada E, Furuta J, et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007;121:301-307
83. Steiner FA, Hong JA, Fischette MR, et al. Sequential 5-aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 2005;24:2386-2397
84. Konduri SD, Srivenugopal KS, Yanamandra N, et al. Promoter methylation and silencind of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human gliomas cells. Oncogene 2003;22:4509-4516
85. Jiang P, Watanabe H, Okada G, et al. Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic carcinoma. Cancer Sci 2006;97:1267-1272
86. Rao CN, Segawa T, Navari JR, et al. Methylation of TFPI-2 gene is not the sole cause of its silencing. Int J Oncol 2003;22:843-848
87. Kempaiah P, Chand HS, Kisiel W. Identification of a human TFPI-2 slice variant that is upregulated in human tumor tissue. Mol Cancer 2007;6:20-31
88. Torres-Collado AX, Kisiel W, Iruela-Arispe ML, Rodriguez-Manzaneque JC. ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2. J Biol Chem 2006;281:17827-17837
89. Jin M, Udagawa K, Miyagi E, et al. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Gynecol Oncol 2001;83:325-333
90. Lakka SS, Konduri SD, Mohanam S, Nicolson GL, Rao JS. In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. Clin Exp Metastasis 2000;18:239-244
91. Konduri SD, Rao CN, Chandrasekar N, et al. A novel function of tissue factor pathway inhibitor-2 (TFPI-2) in human glioma invasion. Oncogene 2001;20:6938-6945
92. Rao CN, Cook B, Liu Y, et al. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Int J Cancer 1998;76:749-756
93. Konduri SD, Tasiou A, Chandrasekar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 1998;76:749-756
94. Konduri SD, Tasiou A, Chandrasekar N, Nicolson GL, Rao JS. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 2000;18:303-308
95. Carroll V, Binder B. The role of the plasminogen activation system in cancer. Semin Thromb Hemost 1999;25:183-197
96. Siiteri JE, Koistinen HAT, Salem HAT, Bohn H, Seppaelae M. Placental protein 5 is related to blood coagulation and fibrinolytic systems. Life Sci 1982;30:1885-1891
97. Rao CN, Mohanam S, Puppala A, Rao JS. Regulation of pro-MMP-1 and pro-MMP-3 activation by tissue factor pathway inhibitor-2/matrix associated serine protease inhibitor. Biochem Biophys Res Commun 1999;255:94-98
98. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001;107:1117-1126
99. Du X, Chand HS, Kisiel W. Human tissue factor pathway inhibitor-2 does not bind or inhibit activated matrix metalloproteinase-1. Biochim Biophys Acta 2003;1621:242-245
100. Kondraganti S, Gondi CS, Gujrati M, et al. Restoration of tissue factor patway inhibitor inhibits invasion and trumor growth in vitro and in vivo a malignant meningioma cell line. Int J Oncol 2006;29:25-32
101. Sun Y, Xie M, Liu M, Jin D, Li P. Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2. Laryngoscope 2006;116:596-601
102. Tasiou A, Konduri SD, Yanamandra N, et al. A novel role of tissue factor pathway inhibitor-2 in apoptosis of malignant human gliomas. Int J Oncol 2001;19:591-597
103. George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor patway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res 2007;13:3507-3517
104. Shoji M, Hancock WW, Abe K, et al. Activation of blood coagulation and angiogenesis in cancer. Am J Pathol 1998;152:399-411
105. Rao LVM. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992;11:249-266
106. Neaud V, Hisaka T, Monvoisin A, et al. Paradoxical proinvasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells. J Biol Chem 2000;275:35565-35569
107. Yanamandra N, Kondraganti S, Gondi CS, et al. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer 2005;115:998-1005
108. Ivanciu L, Gerard RD, Tang H, Lupu F, Lupu C. Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis. Arterioscler Thromb Vasc Biol 2007;27:310-316
109. Xu Z, Maiti D, Kisiel W, Duh EL. Tissue factor pathway inhibitor-2 is up-regulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler Thromb Vasc Biol 2006;26:2819-2825
110. Ruf W, Seftor EA, Petrovan RJ, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003;63:5381-5389
111. Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000;96:3049-3055
112. Ichinose A, Takeya H, Espling E, Iwanaga S, Kisiel W, Davie EW. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Commun 1990;172:1139-1144
113. Sierko E, Tokajuk P, Ramlau R, et al. Immunohistochemical localization of protein Z (ZP) and protein Z-dependent protease inhibitor (ZPI) in situ in human malignant tumors, [abstract] J Thromb Haemost 2005;3(Suppl 1):P0718
114. Sierko E, Wojtukiewicz MZ, Tokajuk P, et al. Expression of protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) in situ in human malignant tissues [abstract]. Blood 2005;106:1028
115. Sierko E, Ramlau R, Zimnoch L, Broze GJ, Wojtukiewicz M. Expression of protein Z-dependent protease inhibitor (ZPI) in situ in different malignant tumors [abstract]. Blood 2004;104:3959
116. Sierko E, Tokajuk P, Ramlau R, Zimnoch L, Kisiel W, Wojtukiewicz M. Localization of protein Z (PZ) in situ in human neoplastic tissues. [abstract] Blood 2004;104:3958
117. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002;13:657-670
118. Wojtukiewicz MZ, Rucinska M, Kloczko J, Dib A, Galar M. Profiles of plasma serpins in patients with advanced malignant melanoma, gastric cancer and breast cancer. Haemostasis 1998;28:7-13
119. Andersen BS, Rahr HB, Sorensen JV. Determination of coagulation inhibitor levels and resistance to activated protein C in patients undergoing gastric surgery for benign and malignant disorders. Haemostasis 1997;27:157-162
120. Honegger H, Anderson N, Hewitt LA, Tullis JL. Antithrombin III profiles in malignancy, relationship between primary tumors and metastatic sites. Thromb Haemost 1981;46:500-503
121. Onizuka K, Migita S, Yamada H, Matsumoto I. Serum protein fractions in patients with laryngeal cancer undergoing radiation therapy. Possibility as a prognostic factor, [in Japanese] [abstract] Fukuoka Igaku Zasshi 1999;90:46-58
122. Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004;98:93-98
123. Bartoloni C, Guidi L, Tricerri A, et al. Latent coagulation disorders evaluated by the assay of plasma thrombin-antithrombin III complex in a large series of 'solid tumors'. Oncology 1992;49:426-430
124. Ozyilkan O, Baltali E, Ozdemir O, Tekuzman G, Kirazli S, Firat D. Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer. Tumori 1998;84:364-367
125. Wojtukiewicz MZ, Tang TG, Ciarelli JJ, et al. Thrombin increases the metastatic potential of tumor cell. Int J Cancer 1993;54:793-806
126. Wojtukiewicz MZ, Tang TG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased αIIbß3 expression on the cell surface. Thromb Res 1992;68:233-245
127. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004;30:95-108
128. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999;285:1926-1928
129. Falanga A, Rickles FR. Patophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999;25:173-182
130. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006;32(suppl 1):49-60
131. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-56
132. Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000;83:639-643
133. Ellis CN, Boggs HW, Slagle GW, Cole PA, Coyle DJ, Blakemore WS. Protein C activity, stage of disease, and vascular thrombosis in colon carcinoma. Am J Surg 1992;163:78-81
134. Green D, Maliekel K, Sushko E, Akhtar R, Soff GA. Activated-protein-C resistance in cancer patients. Haemostasis 1997;27:112-118
135. De Lucia D, De Francesco F, Marotta R, et al. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma. Exp Oncol 2005;27:159-161
136. De Lucia D, De Vita F, Orditura M, et al. Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C. Tumori 1997;83:948-952
137. Paspatis GA, Sfyridaki A, Papanikolaou N, et al. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb 2002;32:2-7
138. Nijziel MR, van Oerle R, Christella M, et al. Acquired resistance to activated protein C in breast cancer patients. Br J Haematol 2003;120:117-122
139. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (APCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 2006;134:399-405
140. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990;93:516-521
141. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991;67:1377-1381
142. Nijziel MR, van Oerle R, van Pampus EC, de Vet HC, Hillen HF, Hamulyák K. Increased D-dimer levels correlate with binding of activated protein C, but not tissue factor expression, on peripheral blood monocytes in cancer patients. Am J Hematol 2000;64:282-286
143. Cheng T, Liu D, Griffin JH, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9:338-342
144. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR-1-dependent sphingosinel-phosphate receptor-1 crossactivation. Blood 2005;105:3178-3184
145. Guo H, Liu D, Gelbard H, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 2. Neuron 2004;41:563-572
146. Wojtukiewicz MZ, Tang TG, Ben-Josef E, Renaud C, Walz DA, Honn KV. Solid tumor cells express functional "tethered ligand" thrombin receptor. Cancer Res 1995;55:698-704
147. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 cell induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003;162:1503-1513
148. Black PC, Mize GJ, Karlin P, et al. Overexpression of protease-activated receptors-1,-2, and-4 (PAR-1, -2, and -4) in prostate cancer. Prostate 2007;67:743-756
149. Kaufmann R, Rahn S, Pollrich K, et al. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4. J Cell Physiol 2007;211:699-707
150. Beaulieu LM, Church FC. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res 2007;313:677-687
151. Granovsky-Grisaru S, Zaidoun S, Grisaru D, et al. The pattern of protease activated receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol Oncol 2006;103:802-806
152. Ghio P, Cappia S, Selvaggi G, et al. Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancer. Clin Lung Cancer 2006;7:395-400
153. Bergmann S, Junker K, Henklein P, Hollenberg MD, Settmacher U, Kaufmann R. PAR-type thrombin receptors in renal carcinoma cells: PAR1-mediated EGFR activation promotes cell migration. Oncol Rep 2006;15:889-893
154. Massi D, Naldini A, Ardinghi C, et al. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 2005;36:676-685
155. Zhang X, Hunt JL, Landsittel DP, et al. Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. Clin Cancer Res 2004;10:8451-8459
156. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller U, Bar-Shavit R. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 2005;113:372-378
157. Rudroff C, Seibold S, Kaufmann R, et al. Expression of the thrombin receptor PAR-1 correlates with tumour cell differentiation of pancreatic adenocarcinoma in vitro. Clin Exp Metastasis 2002;19:181-189
158. Okamoto T, Nishibori M, Sawada K, et al. The effects of stimulating protease-activated receptor-1 and -2 in A172 human glioblastoma. J Neural Transm 2001;108:125-140
159. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998;4:909-914
160. Pleyer L, Went P, Russ G, et al. Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C. Wien Klin Wochenschr 2007;119:254-258
161. Nguyen M, Arkell J, Jackson CJ. Activated protein C directly activates human endothelial gelatinase A. J Biol Chem 2000;275:9095-9098
162. Papadopoulou S, Scorilas A, Arnogianaki N, et al. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol 2001;22:383-389
163. Juuti A, Lundin I, Nordling S, Louhimo J, Haglud C. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology 2006;71:61-68
164. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 2007;29:564-572
165. Wu CY, Wu MS, Chen YJ, et al. Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 2007;43:799-808
166. Uchiba M, Okajima K, Oike Y, et al. Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res 2004;95:34-41
167. Tsuneyoshi N, Fukudome K, Horiguchi S, et al. Expression and anticoagulant function of the endothelial cell protein C receptor (EPCR) in cancer cell lines. Thromb Haemost 2001;85:356-361
168. Scheffer GL, Flens MJ, Hageman S, Izquierdo MA, Shoemaker RH, Scheper RJ. Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells. Eur J Cancer 2002;38:1535-1542
169. Wang X, Wang E, Kavanagh JJ, Freedman SS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005;3:25
170. Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983;258:163-168
171. Sierko E, Tokajuk P, Zimnoch L, Wojtukiewicz MZ. The location of components of fibrinolytic system in laryngeal cancer. [in Polish] Pol Merkur Lekarski. 2003;15:81-85
172. Wakita T, Hayashi T, Nishioka J, et al. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreases in renal cell carcinoma. Int J Cancer 2004;108:516-523
173. Castello R, Landete JM, Espana F, et al. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer. Thromb Res 2007;120:753-762
174. Ordonez N-G. Transitional cell carcinomas of the ovary and bladder are immunophenotypically different. Histopathology 2000;36:433-438
175. Ogawa H, Yonezawa S, Maruyama I, et al. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett 2000;149:95-103
176. Hamatake M, Ishida T, Mitsudomi T, Akazawa K, Sugimachi K. Prognostic value and pathological correlation of thrombomodulin in squamous cell carcinoma of the human lung. Clin Cancer Res 1996;2:763-766
177. Tezuka Y, Yonezawa S, Maruyama I, et al. Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. Cancer Res 1995;55:4196-4200
178. Tamura A, Hebisawa A, Hayashi K, et al. Prognostic significance of thrombomodulin expression and vascular invasion in stage I squamous cell carcinoma of the lung. Lung Cancer 2001;34:375-382
179. Tabata M, Sugihara K, Yonezawa S, Yamashita S, Maruyma I. An immunihistochemical study of thrombomodulin in oral squamous cell carcinoma and its association with invasive and metastatic potential. J Oral Pathol Med 1997;26:258-264
180. Hernández Caspar R, de los Toyos JR, Alvarez Marcos C, Riera JR, Sampedro A. Qualitative immunohistochemical analyses of the expression of the E-cadherin, thrombomodulin, CD44H and CD44v6 in primary tumours of the pharynx, larynx squamous cell carcinoma and their lymph node metastases. Anal Cell Pathol 1999;18:183-190
181. Kim SJ, Shiba E, Ischi H, et al. Thrombomodulin is a new biological and prognostic marker for breast cancer: an Immunohistochemical study. Anticancer Res 1997;17:2319-2323
182. Hanly AM, Redmond M, Winter DC, et al. Thrombomodulin expression in colorectal carcinoma is protective and correlates with survival. Br J Cancer 2006;94:1320-1325
183. Wilhelm S, Schmitt M, Parkinson J, Kuhn W, Graeff H, Wilhelm OG. Thrombomodulin, a receptor for serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc. Int J Oncol 1998;13:645-651
184. Oikawa T, Kushuhara M, Ischikawa S, et al. Production of endothelin-1 and thrombomodulin by human pancreatic canccer cells. Br J Cancer 1994;69:1059-1064
185. Wojtukiewicz MZ, Zimnoch L, Kloczko J, et al. Heterogeneous expression of endothelial cell-associated proteins in gliomas of different malignancy. In: Messmer K, Kubier WM, eds. 6th World Congress for Microcirculation. Bologna, Italy: Monduzzi Editore; 1996:1007-1010
186. Maruno M, Yoshimine T, Isaka T, Kuroda R, Ischi H, Hayakawa TJ. Expression of thrombolmodulin in astrocytomas of various malignancy and in gliotic and normal brains. J Neurooncol 1994;19:155-160
187. Furuta J, Kaneda A, Umebayashi Y, Otsuka F, Sugimura T, Ushijama T. Silencing of the thrombomodulin gene in human malignant melanoma. Melanoma Res 2005;15:15-20
188. Zhang Y, Weiler-Guettler H, Chen J, et al. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest 1998;101:1301-1309
189. Huang HC, Shi GY, Jiang SJ, et al. Thrombomodulin-mediated cell adhesion: involvement of its lectin-like domain. J Biol Chem 2003;278:46750-46759
190. Matsushita Y, Yoshiie K, Imamura Y, et al. A subcloned human esophageal squamous cell carcinoma cell line with low thrombomodulin expression showed increased invasiveness compared with a high thrombomodulin - expressing clone -thrombomodulin as a possible candidate for an adhesion molecule of squamous cell carcinoma. Cancer Lett 1998;127:195-201
191. Suechiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology 1995;21:1285-1290
192. Iino S, Abeyama K, Kawahara K, et al. The antimetastatic role of thrombomodulin expression in islet cell-derived tumors and its diagnostic value. Clin Cancer Res 2004;10:6179-6188
193. Hosaka Y, Higuchi T, Tsamagari M, Ischi H. Inhibition of invasion and experimental metastasis of murine melanoma cells by human soluble thrombomodulin. Cancer Lett 2000;161:231-240
194. Hopewell JW, Calvo W, Jaenke R, Reinhold HS, Robbins ME, Whitehouse EM. Microvasculature and radiation damage. Recent Results Cancer Res 1993;130:1-16
195. Lyubimova N, Hopewell JW. Experimental evidence to support the hypothesis that damage to vascular endothelium plays the primary role in the development of late radiation - induced CNS injury. Br J Radiol 2004;77:488-492
196. Wang J, Zheng H, Ou X, Fink LM, Hauer-Jensen M. Deficiency of microvascular thrombomodulin and up-regulation of protease-activated receptor-1 in irradiaed rat intestine. Am J Pathol 2002;160:2063-2072
197. Wang J, Boerma M, Fu Q, Hauer-Jensen M. Significance of endothelial dysfunction in the pathogenesis of early and delayed radiation enteropathy. World J Gastroenterol 2007;13:3047-3055
198. Phillips DJ, Greengard JS, Fernandez JA, et al. Protein S an antithrombotic factor, is synthesized and released by neural tumor cells. J Neurochem 1993;61:344-347
199. Wimmel A, Rohner I, Ramaswamy A, et al. Synthesis and secrection of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. Cancer 1999;86:43-49
200. Anderson HA, Maylock CA, Williams JA, Paweletz CP, Shu H, Shacter E. Serum-derived protein S binds to phosphatidilserine and stimulates the phagocytosis of apoptotic cells. Nat Immunol 2003;4:87-91
201. Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of thrombin-thrombomodulin complex. J Biol Chem 1995;270:25336-25339
202. Rezende SM, Simmonds RE, Lane DA. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004;103:1192-1201
203. Heiring C, Dahlback B, Muller YA. Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family. J Biol Chem 2004;279:6952-6958
204. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro3 family. Science 2001;293:306-311
205. Tollefsen DM. Heparin cofactor II modulates the response to vascular injury. Arterioscler Thromb Vasc Biol 2007;27:454-460
206. Tollefsen DM. Heparin cofactor II deficiency. Arch Pathol Lab Med 2002;126:1394-1400
207. Kario K, Matsuo T, Kodama K, Katayama S, Kobayashi H. Preferential consumption of heparin cofactor II in disseminated intravascular coagulation associated with promyelocytic leukemia. Thromb Res 1992;66:435-444
208. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:635-643
209. Okusa Y, Ichikura T, Mochzuki H. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Cancer 1999;85:1033-1038
210. Harvey SR, Sait SNJ, Xu I, Bailey JL, Penetrante RM, Marcus G. Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am J Pathol 1999;155:1115-1120
211. Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 1991;51:3522-3525
212. Evans CP, Elfman F, Parangi S, Conn M, Cuhna G, Shuman MA. Inhibition of protease cancer neovascularization and growth by urokinase-plasminogen activator receptor blockage. Cancer Res 1997;57:3594-3599
213. Kuhn W, Schmalfeld B, Reuning U, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FOGO IIIc. Br J Cancer 1999;79:1746-1751
214. de Witte JH, Sweep CG, Klijn JG, et al. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br J Cancer 1999;80:286-294
215. Franks AJ, Elis E. Immunohistochemical localization of tissue plasminogen activator in human brain tumors. Br J Cancer 1989;59:463-466
216. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularisation. Nat Med 1998;4:923-927
217. Carmeliet P, Moons L, Dewerchin M, et al. Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and plasminogen system. Ann N Y Acad Sci 1997;811:191-206
218. Heymans S, Luttun A, Nuyens D, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135-1142
219. Manders P, Tjan-Heijnen VC, Span PN, et al. Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res 2004;64:659-664
220. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer. Int J Cancer 1992;50:345-348
221. Sakakibara T, Hibi K, Koike M, et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer 2005;93:799-803
222. Sakakibara T, Hibi K, Koike M, et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Sci 2006;97:395-399
223. Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res 2004;10:1375-1378
224. Nagayama M, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer 1994;73:1398-1405
225. Hanekom GS, Stubbings HM, Kidson SH. The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma. Cancer Detect Prev 2002;26:50-59
226. Whitley BR, Palmieri D, Twerdi CD, Church FC. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 2004;296:151-162
227. Friedl P, Bröcker EB. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci 2000;57:41-64
228. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990;111:783-792
229. Nykjaer A, Conese M, Christensen EI, et al. Recycling of the urokinase receptor upon internalization of the u-PA: serpin complexes. EMBO J 1997;16:2610-2620
230. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-32388
231. Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronect. J Cell Physiol 2001;189:23-33
232. Takahashi T, Suzuki K, Ihara H, Mogami H, Kazui T, Urano T. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin. Semin Thromb Hemost 2005;31:356-363
233. Scherrer A, Kruithof EK, Grob JP. Plasminogen activator inhibitor-2 in patients with monocytic leukemia. Leukemia 1991;5:479-486
234. Borgfeldt C, Bendahl PO, Gustavsson B, et al. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Int J Cancer 2003;107:658-665
235. Yoshino H, Endo Y, Watanabe Y, Sasaki T. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer 1998;78:833-839
236. Zhao E, Han D, Yu Z, Fan E, Li Y, Zhou Z. Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2002;16:599-602
237. Nordengren J, Fredstorp Lidebring M, Bendahl PO, et al. High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer 2002;97:379-385
238. Foca C, Moses EK, Quinn MA, Rice GE. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas. Gynecol Oncol 2000;79:244-250
239. Osmak M, Babic D, Abramic M, Milicic D, Vrhovec I, Skrk J. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas. Neoplasma 2001;48:462-467
240. Wojtukiewicz MZ, Sierko E, Zacharski LR, Rozanska-Kudelska M, Zimnoch L, Kisiel W. Occurence of components of fibrinolytic pathways in situ in laryngeal cancer. Semin Thromb Hemost 2003;29:317-320
241. Mueller BM, Yu YB, Laug WE. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid / scid mice. Proc Natl Acad Sci USA 1995;92:205-209
242. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EK. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993;53:6051-6057
243. Yu H, Maurer F, Medcalf RL. Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 2002;99:2810-2818
244. Genton C, Kruithof EK, Schleuning WD. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J Cell Biol 1987;104:705-712
245. Medcalf RL, Kruithof EK, Schleuning WD. Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor / cachectin-responsive genes. J Exp Med 1988;168:751-759
246. Darnell GA, Antalis TM, Johnstone RW, et al. Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 2003;23:6520-6532
247. Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 1995;270:27894-27904
248. Dickinson JL, Norris BJ, Jensen PH, Antalis TM. The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis. Cell Death Differ 1998;5:163-171
249. Fish RJ, Kruithof EK. Evidence for serpinB2-independent protection from TNF-alpha-induced apoptosis. Exp Cell Res 2006;312:350-361
250. Stief TW, Radtke KP, Heimburger N. Inhibition of urokinase by protein C-inhibitor (PCI). Evidence for identity of PCI and plasminogen activator inhibitor 3. Biol Chem Hoppe Seyler 1987;368:1427-1433
251. Crisp RJ, Knauer MF, Knauer DJ. Protease nexin 1 is a potent urinary plasminogen activator inhibitor in the presence of collagen type IV. J Biol Chem 2002;277:47285-47291
252. Rossignol P, Ho-Tin-Noe B, Vranckx R, et al. Protease nexin-1 inhibits plasminogen activation-induced apoptosis of adherent cells. J Biol Chem 2004;279:10346-10356
253. Buchholz M, Biebl A, Neesse A, et al. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res 2003;63:4945-4951
254. Ozyilkan O, Baltali E, Ozdemir O, Tekuzman G, Kirazli S, Firat D. Haemostatic changes; plasma levels of alpha2-antiplasmin-plasmin complex and thrombin-antithrombin III complex in female breast cancer. Tumori 1998;84:364-367
255. Taguchi O, Gabazza EC, Yoshida M, Yamakami T, Kobayashi H, Shima T. High plasma level of plasmin-alpha 2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clin Chim Acta 1996;244:69-81
256. Hayashido Y, Hamana T, Ishida Y, Shintani T, Koizumi K, Okamoto T. Induction of alpha2-antiplasmin inhibits E-cadherin processing mediated by the plasminogen activator/plasmin system, leading to suppression of progression of oral squamous cell carcinoma via upregulation of cell-cell adhesion. Oncol Rep 2007;17:417-423
257. Reijerkerk A, Voest EE, Gebbink MF. No grip, no growth: the conceptual basis of excessive proteolysis in the treatment of cancer. Eur J Cancer 2000;36:1695-1705
258. Meijers JC, Oudijk EJ, Mosnier LO, et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000;108:518-523
259. Hataji O, Taguchi O, Gabazza EC, et al. Increased circulating levels of thrombin -acivatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004;76:214-219
260. Nakasaki T, Wada H, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002;69:247-254
261. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma. Cancer 2000;88:295-301
262. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894-898
263. Bromberg ME, Sundaram R, Homer RJ, Garen A, Konigsberg WH. Role of tissue factor in metastasis: function of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82:88-92
264. Amirkhosravi A, Meyer T, Warnes G, et al. Pentoxyfilline inhibits hypoxia-induced upregulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb Haemost 1998;80:598-602
265. Fenton JW II, Shen GX, Minnear FL, et al. Statins induce hypothrombotic states? Clin Appl Thromb Hemost 2000;6:18-21
266. Rak J, Mitsuhashi Y, Sheehan C, et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000;60:490-498
267. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-5101
268. Attoub S, Rivat C, Rodrigues S, et al. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 2002;62:4879-4883
269. Fletcher L. Approval heralds new generation of kinase inhibitors? Nat Biotechnol 2001;19:599-600
270. Russo P, Ottoboni C, Falugi C, et al. Cellular effects of a new farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer cell line model system HCT-116. Ann N Y Acad Sci 1999;886:252-256
271. Cirillo P, Golino P, Ragni M, et al. Long-lasting antithrombotic effects of a single dose of human recombinant, active site-blocked factor VII: insights into possible mechanism(s) of action. J Thromb Haemost 2003;1:992-998
272. Soderstrom T, Hedner U, Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J Vasc Surg 2001;33:1072-1079
273. Rossi C, Hess S, Eckl RW, et al. Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice. J Thromb Haemost 2006;4:608-613
274. Tomaru T, Nakamura F, Miwa AY, et al. Antithrombin and thrombolytic effect of a new antithrombin agent: angioscopic and angiographic comparison with heparin or batroxobin. J Interv Cardiol 1994;7:409-419
275. Sakuragi T, Sakao Y, Furukawa K, et al. Successful management of acute pulmonary embolism after surgery for lung cancer. Eur J Cardiothorac Surg 2003;24:580-587
276. Asanuma K, Wakabayashi H, Okuyama N, et al. Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis. Oncology 2004;67:166-173
277. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. J Biol Chem 1999;274:23969-23976
278. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol 1993;264:1302-1307
279. Hua Y, Keep RF, Schallert T, Hoff JT, Xi G. A thrombin inhibitor reduces brain edema, glima mass and neurological deficits in a rat glioma model. Acta Neurochir Suppl 2003;86:503-506
280. Hua Y, Tang LL, Keep RF, et al. Systemic use of argatroban reduces tumor mass, attenuates neurological deficits and prolongs survival time in rat gliomas models. Acta Neurochir Suppl 2005;95:403-406
281. Hua Y, Tang LL, Keep RF, et al. The role of thrombin in gliomas. J Thromb Haemost 2005;3:1917-1923
282. Sarker KP, Biswas KK, Yamaji K, et al. Inhibition of thrombin-induced vascular endothelial growth factor production in human neuroblastoma (NB-1) cells by argatroban. Pathophysiol Haemost Thromb 2005;34:41-47
283. Gasic GJ, Gasic TB, Steward CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968;61:46-52
284. Chiang HS, Swaim MW, Huang TF. The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells. Br J Cancer 1995;71:265-270
285. Chiang HS, Swaim MW, Huang TF. Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin. Breast Cancer Res Treat 1995;33:225-235
286. Sheu JR, Lin CH, Pung HC, Teng CM, Huang TF. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits tumor cell-induced platelet aggregation. Jpn J Cancer Res 1993;84:1062-1071
287. Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revised: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001;98:3352-3357
288. Bernard GR, Margolis BD, Shanies HM, et al. Extended Evaluation of Recombinant Human Activated Protein C United States Investigators. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in sepsis. Chest 2004;125:2206-2216
289. Shi X, Gangedharan B, Brass LF, Ruf W, Mueller BM. Protease-activated receptors (PAR-1 and PAR-2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2:395-402
290. Zania P, Kritikou S, Flordellis CS, Maragoudakis ME, Tsopanoglou NE. Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther 2006;318:246-254
291. Domiano BP, Derian CK, Maryanoff BE, Zhang HC, Gordon PA. RWJ-58259: a selective antagonists of protease activated receptor-1. Cardiovasc Drug Rev 2003;21:313-326
292. Engelberg H. Action of heparin that may effect the malignant process. Cancer 1999;85:257-272
293. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight- heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982
294. Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight-heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445
295. Hirsh J, Siragusa S, Cosmi B, Ginsber JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995;74:360-363
296. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight-heparin and unfractionated heparin in the treatment of patients with acute venous thromboembolism. Am J Med 1996;100:269-277
297. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135
298. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low molecular weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271
299. Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin coumarin derivates on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129
300. Vignoli A, Marchetti M, Balducci D, Barbui T, Falanga A. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 2006;91:207-214
301. Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inibitor. Thromb Haemost 2004;92:627-633
302. Niers TM, Klerk CP, DiNisio M, et al. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007;61:195-207
303. Parish CR, Freeman C, Brown KJ, et al. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 1999;59:3433-3441
304. Colin S, Jeanny JC, Mascarelli F, et al. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogeneous basic fibroblast growth factor. Mol Pharmacol 1999;55:74-82
305. Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 1995;83:357-360
306. Soker S, Goldstaub D, Svahn CM, Vlodavsky I, Levi BZ, Neufeld G. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF to its receptors. Biochem Biophys Res Commun 1994;203:1339-1347
307. 165-mediated angiogenesis. Int J Microcirc Clin Exp 1997;17:314-321
308. Norrby K, Østergaard P. Basic fibroblast growt factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-wieght than high-molecular-weight heparin. Int J Microcirc Clin Exp 1996;16:8-15
309. Balzarotti M, Fontana F, Marras C, et al. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res 2006;16:245-250
310. Chopra H, Timar J, Rong X, et al. Is there a role for the tumor cell integrin αIIbß3 in tumor-cell induced platelet aggregation. Clin Exp Metastasis 1992;10:125-137
311. Coller BS. Anti-GpIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001;86:427-443
312. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin Hb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995;74:282-290
313. Trikha M, Zhou Z, Timar J, et al. Multiple roles for platelet GPIIb/IIa and platelet alpha v beta 3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002;62:2824-2833
314. Amirkhosravi A, Mousa SA, Amaya M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb-IIIa antagonist XV454. Thromb Haemost 2003;90:549-554
315. Sheu JR, Lin CH, Chung JI, Teng CM, Huang TF. Triflavin, an Arg-Gly-Asp containing snake venom peptide, inhibits aggregation of human platelets induced by human hepatoma cell line. Thromb Res 1992;66:679-691
316. Chiang HS, Swaim MW, Huang TF. Characterization of platelet aggregation induced by human colon adenocarcinoma cells and its inhibition by snake venom peptides, trigramin and rhodostomin. Br J Haematol 1994;87:325-331
317. Chiang HS, Swaim MW, Huang TF. The Arg-Gly-Asp-containing peptide, rhodostomin, inhibits in vitro cell adhesion to extracellular matrices and platelet aggregation caused by saos-2 human osteosarcoma cells. Br J Cancer 1995;71:265-270
318. Chiang HS, Swaim MW, Huang TF. Characterization of platelet aggregation induced by human breast carcinoma and its inhibition by snake venom peptides, trigramin and rhodostomin. Breast Cancer Res Treat 1995;33:225-235
319. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-148
320. da Silva MS, Horton JA, Wijelath JM, et al. Heparin modulates integrin-mediated cellular adhesion: specificity of interaction with alpha and beta integrin subunits. Cell Adhes Commun 2003;10:59-67
321. Ludwig RJ, Beohme B, Podda M, et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004;64:2743-2750
322. Wang J, Zheng H, Ou X, et al. Hirudin ameliorates intestinal radiation toxicity in the rat: support for thrombin inhibition as strategy to minimize side-effects after radiation therapy and as countermeasure against radiation exposure. J Thromb Haemost 2004;2:2027-2035
323. Glantz MJ, Burger PC, Friedman AH, Radtke RA, Massey EW, Schold SC Jr. Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 1994;44:2020-2027
324. Wang J, Zheng H, Qiu X, Kulkarni A, Fink LM, HauerJansen M. Modulation of the intestinal response to ionizing radiation by anticoagulant and non-anticoagulant heparins. Thromb Haemost 2005;94:1054-1059
325. Wang J, Albertson CM, Zheng H, Fink LM, Herbert JM, Hauer-Jensen M. Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine. Thromb Haemost 2002;87:122-128
326. Akyurek S, Atahan L, Cengiz M, et al. Effect of ticlopidine in the prevention of radiation enteropathy. Br J Radiol 2006;79:409-414
327. Mouthon MA, Gaugler MH, Vandamme M, Gourmelon P, Wagemaker G, Van der Meeren A. Ticlopidine inhibits the prothrombotic effects of thrombopoietin and ameliorates survival after supralethal total body irradiation. Thromb Haemost 2002;87:323-328